These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
220 related articles for article (PubMed ID: 7905629)
1. Assessment of c-erbB-2 amplification by immunohistochemistry in paraffin-embedded breast cancer. Kerns BJ; Jordan PA; Huper G; Marks JR; Iglehart JD; Layfied LJ Mod Pathol; 1993 Nov; 6(6):673-8. PubMed ID: 7905629 [TBL] [Abstract][Full Text] [Related]
2. c-erbB-2 expression in breast cancer detected by immunoblotting and immunohistochemistry. Kerns BJ; Pence JC; Huper G; Kinney RB; Iglehart JD J Histochem Cytochem; 1990 Dec; 38(12):1823-30. PubMed ID: 1979342 [TBL] [Abstract][Full Text] [Related]
3. Increased erbB-2 gene copies and expression in multiple stages of breast cancer. Iglehart JD; Kraus MH; Langton BC; Huper G; Kerns BJ; Marks JR Cancer Res; 1990 Oct; 50(20):6701-7. PubMed ID: 2208136 [TBL] [Abstract][Full Text] [Related]
4. Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Press MF; Pike MC; Chazin VR; Hung G; Udove JA; Markowicz M; Danyluk J; Godolphin W; Sliwkowski M; Akita R Cancer Res; 1993 Oct; 53(20):4960-70. PubMed ID: 8104689 [TBL] [Abstract][Full Text] [Related]
5. Chromosome 11q13, c-erbB-2, and c-myc amplification in invasive breast carcinoma: clinicopathologic correlations. Gaffey MJ; Frierson HF; Williams ME Mod Pathol; 1993 Nov; 6(6):654-9. PubMed ID: 7905628 [TBL] [Abstract][Full Text] [Related]
6. An immunohistochemical and in situ hybridization study of c-myc and c-erbB-2 expression in primary human breast carcinomas. Walker RA; Senior PV; Jones JL; Critchley DR; Varley JM J Pathol; 1989 Jun; 158(2):97-105. PubMed ID: 2569035 [TBL] [Abstract][Full Text] [Related]
7. Overexpression of erbB-2 or EGF receptor proteins present in early stage mammary carcinoma is detected simultaneously in matched primary tumors and regional metastases. Lacroix H; Iglehart JD; Skinner MA; Kraus MH Oncogene; 1989 Feb; 4(2):145-51. PubMed ID: 2564657 [TBL] [Abstract][Full Text] [Related]
8. Determination of Her-2/Neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization. Jimenez RE; Wallis T; Tabasczka P; Visscher DW Mod Pathol; 2000 Jan; 13(1):37-45. PubMed ID: 10658908 [TBL] [Abstract][Full Text] [Related]
9. Overexpression of either c-myc or c-erbB-2/neu proto-oncogenes in human breast carcinomas: correlation with poor prognosis. Guérin M; Barrois M; Terrier MJ; Spielmann M; Riou G Oncogene Res; 1988; 3(1):21-31. PubMed ID: 2905033 [TBL] [Abstract][Full Text] [Related]
10. Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. Berger MS; Locher GW; Saurer S; Gullick WJ; Waterfield MD; Groner B; Hynes NE Cancer Res; 1988 Mar; 48(5):1238-43. PubMed ID: 2893663 [TBL] [Abstract][Full Text] [Related]
11. Oncogene patterns in breast and ovarian carcinomas. Csókay B; Papp J; Besznyák I; Bösze P; Sárosi Z; Tóth J; Zalay Z; Oláh E Eur J Surg Oncol; 1993 Dec; 19(6):593-9. PubMed ID: 7903645 [TBL] [Abstract][Full Text] [Related]
12. What's new in breast cancer? Molecular perspectives of cancer development and the role of the oncogene c-erbB-2 in prognosis and disease. Dawkins HJ; Robbins PD; Smith KL; Sarna M; Harvey JM; Sterrett GF; Papadimitriou JM Pathol Res Pract; 1993 Dec; 189(10):1233-52. PubMed ID: 7910395 [TBL] [Abstract][Full Text] [Related]
13. Prognostic and predictive relevance of c-erbB-2 and ras expression in node positive and negative breast cancer. Giai M; Roagna R; Ponzone R; De Bortoli M; Dati C; Sismondi P Anticancer Res; 1994; 14(3B):1441-50. PubMed ID: 7915096 [TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical detection of the neu protein in tissue sections of human breast tumors with amplified neu DNA. van de Vijver MJ; Mooi WJ; Wisman P; Peterse JL; Nusse R Oncogene; 1988 Feb; 2(2):175-8. PubMed ID: 3285295 [TBL] [Abstract][Full Text] [Related]
15. HER-2 DNA quantification of paraffin-embedded breast carcinomas with LightCycler real-time PCR in comparison to immunohistochemistry and chromogenic in situ hybridization. Ntoulia M; Kaklamanis L; Valavanis C; Kafousi M; Stathopoulos E; Arapantoni P; Mavroudis D; Georgoulias V; Lianidou ES Clin Biochem; 2006 Sep; 39(9):942-6. PubMed ID: 16916505 [TBL] [Abstract][Full Text] [Related]
16. HER2 status in breast cancer determined by IHC and FISH: comparison of the results. Mrozkowiak A; Olszewski WP; Piaścik A; Olszewski WT Pol J Pathol; 2004; 55(4):165-71. PubMed ID: 15757204 [TBL] [Abstract][Full Text] [Related]
17. Analysis of ERBB2 and TOP2A gene status using fluorescence in situ hybridization versus immunohistochemistry in localized breast cancer. Bouchalová K; Trojanec R; Kolár Z; Cwiertka K; Cernáková I; Mihál V; Hajdúch M Neoplasma; 2006; 53(5):393-401. PubMed ID: 17013533 [TBL] [Abstract][Full Text] [Related]
18. Phosphatidylinositol 3-kinase recruitment by p185erbB-2 and erbB-3 is potently induced by neu differentiation factor/heregulin during mitogenesis and is constitutively elevated in growth factor-independent breast carcinoma cells with c-erbB-2 gene amplification. Ram TG; Ethier SP Cell Growth Differ; 1996 May; 7(5):551-61. PubMed ID: 8732665 [TBL] [Abstract][Full Text] [Related]
19. Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization. Persons DL; Borelli KA; Hsu PH Mod Pathol; 1997 Jul; 10(7):720-7. PubMed ID: 9237184 [TBL] [Abstract][Full Text] [Related]
20. Comparison of differential PCR and immunohistochemistry for the evaluation of c-erbB-2 in breast carcinoma and relationship to other prognostic factors. Erdogan S; Ergin M; Tuncer I Neoplasma; 2003; 50(5):326-30. PubMed ID: 14628084 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]